{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:40:55Z","timestamp":1784896855060,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40265-019-01219-5","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T15:35:55Z","timestamp":1573227355000},"page":"1867-1876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-2125","authenticated-orcid":false,"given":"Young Ran","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy Louise","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"1219_CR1","unstructured":"Global Health Estimates 2016: deaths by cause, age, sex, by country and by region, 2000\u20132016. Geneva, World Health Organization. 2018. Accessed 12 Sep 2019."},{"key":"1219_CR2","unstructured":"Rui P, Kang K, Ashman JJ. National hospital ambulatory medical care survey: 2016 emergency department summary tables.\u00a02016.\u00a0\nhttps:\/\/www.cdc.gov\/nchs\/data\/ahcd\/nhamcs_emergency\/2016_ed_web_tables.pdf\n\n."},{"key":"1219_CR3","unstructured":"Center for disease control and prevention: national vital statistics reports, Vol. 67, No. 5, July 26, 2018. Table I\u201312.\u00a0\nhttps:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr67\/nvsr67_05_tables.pdf\n\n."},{"issue":"12","key":"1219_CR4","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3390\/ijms17122120","volume":"17","author":"Catia Cilloniz","year":"2016","unstructured":"Cilloniz C, Martin I, Garcia C, San Jose A, Torres A. Microbial etiology of pneumonia: epidemiology, diagnosis, and resistance patterns. Int J Mol Sci. 2016; 17(12): 2120. (Published online 2016 Dec 16). \nhttps:\/\/doi.org\/10.3390\/ijms17122120\n\n.","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"1219_CR5","first-page":"277","volume":"40","author":"CL Ventola","year":"2015","unstructured":"\u200bVentola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 2015;40(4):277\u201383.","journal-title":"Pharm Ther"},{"key":"1219_CR6","unstructured":"American Thoracic Society: Top 20 Pneumonia Facts 2018.\u00a0\nhttps:\/\/www.thoracic.org\/patients\/patient-resources\/resources\/top-pneumonia-facts.pdf\n\n. Accessed 6 Jun 2019."},{"key":"1219_CR7","unstructured":"National Center for Biotechnology Information. PubChem Database. Tiamulin, CID=443604, \nhttps:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tiamulin\n\n. Accessed 8 Jun 2019."},{"issue":"2","key":"1219_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1358\/dot.2008.44.2.1153446","volume":"44","author":"L Parish","year":"2008","unstructured":"Parish L, Parish J. Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections. Drugs Today (Barc). 2008;44(2):91\u2013102. \nhttps:\/\/doi.org\/10.1358\/dot.2008.44.2.1153446\n\n.","journal-title":"Drugs Today (Barc)."},{"issue":"5","key":"1219_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/jac\/dks001","volume":"67","author":"H Sader","year":"2012","unstructured":"Sader H, Paukner S, Ivezic-Schoenfeld Z, Biedenbach D, Schmitz F, Jones R. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012;67(5):1170\u20135. \nhttps:\/\/doi.org\/10.1093\/jac\/dks001\n\n(Epub 2012 Jan 27).","journal-title":"J Antimicrob Chemother."},{"key":"1219_CR10","doi-asserted-by":"publisher","unstructured":"Eyal Z, Matzov D, Krupkin M, et al. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep. 2016;6:39004. \nhttps:\/\/doi.org\/10.1038\/srep39004\n\n. (Published 2016 Dec 13).","DOI":"10.1038\/srep39004"},{"issue":"Supplement_3","key":"1219_CR11","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/jac\/dkz084","volume":"74","author":"Keith A Rodvold","year":"2019","unstructured":"Rodvold KA. Introduction: lefamulin and pharmacokinetic\/pharmacodynamic rationale to support the dose selection of lefamulin. J Antimicrob Chemother. 2019;74(Supplement_3):iii2\u2013iii4. \nhttps:\/\/doi.org\/10.1093\/jac\/dkz084\n\n.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"9","key":"1219_CR12","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1128\/AAC.00358-13","volume":"57","author":"S Paukner","year":"2013","unstructured":"Paukner S, Sader H, Ivezic-Schoenfeld Z, Biedenbach D, Jones R. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013;57(9):4489\u201395. \nhttps:\/\/doi.org\/10.1128\/AAC.00358-13\n\n(Epub 2013 Jul 8).","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"1219_CR13","doi-asserted-by":"publisher","first-page":"e02158-18","DOI":"10.1128\/AAC.02158-18","volume":"63","author":"R Mendes","year":"2019","unstructured":"Mendes R, Paukner S, Doyle T, et al. Low prevalence of gram-positive isolates showing elevated MIC results during the SENTRY surveillance program for 2015-2016 and characterization of resistance mechanisms. Antimicrob Agens Chemother. 2019;63(4):e02158-18. \nhttps:\/\/doi.org\/10.1128\/AAC.02158-18\n\n(Epub 2019 Jan 22).","journal-title":"Antimicrob Agens Chemother."},{"issue":"1","key":"1219_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1128\/AAC.02033-13","volume":"59","author":"C Rubino","year":"2015","unstructured":"Rubino C, Xue B, Bhavnani S, et al. Population pharmacokinetic analysis for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59(1):282\u20138. \nhttps:\/\/doi.org\/10.1128\/AAC.02033-13\n\n(Epub 2014 Oct 27).","journal-title":"Antimicrob Agents Chemother."},{"key":"1219_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/jac\/dkv442","volume":"71","author":"M Zeitlinger","year":"2016","unstructured":"Zeitlinger M, Schwameis R, Burian A, et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother. 2016;71:1022\u20136. \nhttps:\/\/doi.org\/10.1093\/jac\/dkv442\n\n.","journal-title":"J Antimicrob Chemother."},{"issue":"Supplement_3","key":"1219_CR16","doi-asserted-by":"publisher","first-page":"iii35","DOI":"10.1093\/jac\/dkz089","volume":"74","author":"Sujata M Bhavnani","year":"2019","unstructured":"Bhavnani S, Zhang L, Hammel J, et al. Pharmacokinetic\/pharmacodynamics target attainment analysis to support intravenous and oral lefamulin dose selection for the treatment of patients with community acquired bacterial pneumonia. J Antimicrob Chemother. 2019;74(Supplement_3):iii35\u2013iii41. \nhttps:\/\/doi.org\/10.1093\/jac\/dkz089\n\n.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"1219_CR17","unstructured":"Xenleta (lefamulin) [prescribing information]. King of Prussia, PA: Nabriva Therapeutics US, Inc. 2019."},{"issue":"7","key":"1219_CR18","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1128\/AAC.00627-16","volume":"60","author":"Rodrigo E. Mendes","year":"2016","unstructured":"Mendes R, Farrell D, Flamm R, et al. In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. Antimicrob Agents Chemother. 2016;60(7):4407\u20134411.\u00a0\nhttps:\/\/doi.org\/10.1128\/aac.00627-16\n\n. (Published 2016 Jun 20).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Supplement_3","key":"1219_CR19","doi-asserted-by":"publisher","first-page":"iii5","DOI":"10.1093\/jac\/dkz085","volume":"74","author":"Wolfgang W Wicha","year":"2019","unstructured":"\u200bWicha W, Craig W, Andes D. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. J Antimicrob Chemother. 2019;74(Supplement_3):iii5\u2013iii10.\u00a0\nhttps:\/\/doi.org\/10.1093\/jac\/dkz085\n\n.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Supplement_3","key":"1219_CR20","doi-asserted-by":"publisher","first-page":"iii11","DOI":"10.1093\/jac\/dkz086","volume":"74","author":"Wolfgang W Wicha","year":"2019","unstructured":"\u200bWicha W, Strickmann D, Paukner S. Pharmacokinetics\/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2019;74(Supplement_3):iii11\u2013iii18.\u00a0\nhttps:\/\/doi.org\/10.1093\/jac\/dkz086\n\n.","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"11","key":"1219_CR21","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cid\/ciz090","volume":"69","author":"Thomas M File","year":"2019","unstructured":"\u200bFile T, Goldberg L, Das A, et al. Efficacy and safety of IV-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial. Clin Infect Dis. 2019.\u00a0\nhttps:\/\/doi.org\/10.1093\/cid\/ciz090\n\n. [Epub ahead of print].","journal-title":"Clinical Infectious Diseases"},{"key":"1219_CR22","unstructured":"\u200bAlexander E, et al. Abstract LB6. Presented at: IDWeek. 2018. San Francisco."},{"issue":"5","key":"1219_CR23","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1128\/AAC.02106-12","volume":"57","author":"W Prince","year":"2013","unstructured":"\u200bPrince W, Ivezic-Schoenfeld Z, Lell C, et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013;57(5):2087\u201394.\u00a0\nhttps:\/\/doi.org\/10.1128\/AAC.02106-12\n\n(Epub 2013 Feb 19).","journal-title":"Antimicrob Agents Chemother."},{"key":"1219_CR24","unstructured":"Moxifloxacin. In: Lexi-Drugs [database online]. Hudson, Ohio: Wolters-Kluwer Health.2019. Accessed 15 Sep 2019."},{"key":"1219_CR25","unstructured":"Linezolid. In: Lexi-Drugs [database online]. Hudson, Ohio: Wolters-Kluwer Health. 2019. Accessed 15 Sep 2019."},{"issue":"7","key":"1219_CR26","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"Joshua P. Metlay","year":"2019","unstructured":"Metlay J, Waterer G, Long A, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u2013e67. \nhttps:\/\/doi.org\/10.1164\/rccm.201908-1581st\n\n.","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"1219_CR27","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1378\/chest.06-1426","volume":"131","author":"ML Metersky","year":"2007","unstructured":"Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131:466.","journal-title":"Chest"},{"key":"1219_CR28","doi-asserted-by":"publisher","unstructured":"Paukner S, Gruss A, Jensen J. In vitro activity of lefamulin against sexually transmitted bacterial pathogens. Antimicrob Agents Chemother. 2018;6:25. \nhttps:\/\/doi.org\/10.1128\/aac.02380-17\n\n. (Print 2018 May).","DOI":"10.1128\/aac.02380-17"},{"key":"1219_CR29","doi-asserted-by":"publisher","unstructured":"Jacobsson S, Paukner S, Golparian D, Jensen JS, Unemo M. In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017;61(11):e01497-17. \nhttps:\/\/doi.org\/10.1128\/aac.01497-17\n\n. (Published 2017 Oct 24).","DOI":"10.1128\/aac.01497-17"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01219-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01219-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01219-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:30:16Z","timestamp":1604709016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01219-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1219"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01219-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"8 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}